| For: | Ma W, Baran N. Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy. World J Clin Oncol 2025; 16(7): 104959 [PMID: 40741200 DOI: 10.5306/wjco.v16.i7.104959] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v16/i7/104959.htm |
| Number | Citing Articles |
| 1 |
Kai Yang, Wei Shang, Lu Wang, Jianzhong He, Zhigang Zuo, Quankai Dai, Jialing Liu, Langhong Zeng, Yuntian Yang, Fengjun Cao, Yuandong Yu, Guoxing Wan. Sex-based heterogeneity in response to first-line immunotherapy plus chemotherapy in advanced esophageal squamous-cell carcinoma: a meta-analysis. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1784688
|
| 2 |
Feng Du, Wei Deng, Yanjie Xiao, Rong Yu, Jun Jia. Dynamic survival prediction using longitudinal AGR in unresectable locally advanced esophageal squamous cell carcinoma. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1909638
|
| 3 |
Xuejun Guo, Shuhan Ma, Jingwen Wang, Yilin Fu, Wenxue Ma. Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. Frontiers in Immunology 2026; 16 doi: 10.3389/fimmu.2025.1709852
|
| 4 |
Yi Gan, Yue Li, Li Fang, Yuejun Chen, Desong Yang. Survival benefit and dynamics of CD8+ T cells and tumor-associated macrophages in neoadjuvant immunochemotherapy vs. chemotherapy for locally advanced esophageal squamous cell carcinoma: an IPTW-adjusted real-world study. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1788756
|
| 5 |
Long Zhang, Zehang Zhang, Guochao Zhang, Chao Zheng, Yuzhuo Zhang, Zhichao Zuo, Shuangping Zhang, Yong Li, Yin Li, Qi Xue. Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemoradiotherapy versus Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Real-World, Three-Arm, Retrospective Cohort Study from the Chinese National Cancer Center. Technology in Cancer Research & Treatment 2026; 25 doi: 10.1177/15330338261459197
|
| 6 |
Zhiyu Li, Qiuxi Zhou, Qin Xie, Chenghao Wang, Lin Peng, Yongtao Han, Xuefeng Leng, Yan Miao, Qi Zhang, Wenwu He. Comparative outcomes of neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in locally advanced thoracic esophageal squamous cell carcinoma: a target trial emulation. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1916623
|
| 7 |
Shubhankar Dash, Patryk Firmanty, Monika Chomczyk, Vakul Mohanty, Wenxue Ma, Natalia Baran. Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1749965
|
| 8 |
Yixiang Zhu, Zan Hou, Yiting Sun, Lei Xu, Yuqin Cao, Lijun Liang, Yongkui Yu, Mei Lan, Ming Fan, Lin Peng, Xuefeng Leng, Chenghao Wang, Linrui Gao, Jian Zheng, Lei Wu, Zefen Xiao, Wei Huang, Ming Wu, Wencheng Zhang, Hecheng Li, Qifeng Wang. Neoadjuvant chemoimmunotherapy versus chemoradiotherapy for esophageal squamous cell carcinoma: a multicenter cohort study. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1882240
|
| 9 |
Rui-Ying Zhang, Han Wu, Pei-Xiang Hao, Lu-Lu Guan, Dao Xin, Feng Wang. Acquired resistance to first-line immune checkpoint inhibitors in esophageal squamous cell carcinoma: progression patterns and prognostic implications. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1906395
|
| 10 |
Afsar Ali, Tawqeer Shafi, Imtiyaz Hussain, Ruhit Ashraf. <b>Revolutionizing Autoimmune Disease Management: Cutting-Edge Immunotherapeutic Strategies and Emerging Therapeutic Paradigms</b>. Pan-African Journal of Health and Psychological Sciences 2026; 2(2) doi: 10.64261/txxhnb84
|